| Literature DB >> 35832153 |
Joseph M Escandón1, Eric Santamaría2, Peter A Prieto3, Daniela Duarte-Bateman4, Pedro Ciudad5,6, Megan Pencek1, Howard N Langstein1, Hung-Chi Chen6, Oscar J Manrique1.
Abstract
Several reconstructive methods have been reported to restore the continuity of the aerodigestive tract following resection of pharyngeal and hypopharyngeal cancers. However, high complication rates have been reported after voice prosthesis insertion. In this setting, the ileocolon free flap (ICFF) offers a tubularized flap for reconstruction of the hypopharynx while providing a natural phonation tube. Herein, we systematically reviewed the current evidence on the use of the ICFF for reconstruction of the aerodigestive tract. A systematic literature search was conducted across PubMed MEDLINE, Web of Science, ScienceDirect, Scopus, and Ovid MEDLINE(R). Data on the technical considerations and surgical and functional outcomes were extracted. Twenty-one studies were included. The mean age and follow-up were 54.65 years and 24.72 months, respectively. An isoperistaltic or antiperistaltic standard ICFF, patch flap, or chimeric seromuscular-ICFF can be used depending on the patients' needs. The seromuscular chimeric flap is useful to augment the closure of the distal anastomotic site. The maximum phonation time, frequency, and sound pressure level (dB) were higher with ileal segments of 7 to 15 cm. The incidence of postoperative leakage ranged from 0 to 13.3%, and the majority was occurring at the coloesophageal junction. The revision rate of the microanastomosis ranged from 0 to 16.6%. The ICFF provides a reliable and versatile alternative for reconstruction of middle-size defects of the aerodigestive tract. Its three-dimensional configuration and functional anatomy encourage early speech and deglutition without a prosthetic valve and minimal donor-site morbidity. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: colon; free tissue flaps; hypopharyngeal neoplasms; ileum; laryngectomy; reconstructive surgical procedures
Year: 2022 PMID: 35832153 PMCID: PMC9142245 DOI: 10.1055/s-0042-1748652
Source DB: PubMed Journal: Arch Plast Surg ISSN: 2234-6163
Inclusion and exclusion criteria
|
|
| • Patient-based studies |
| • Reconstructive procedures of the aerodigestive tract using an ileocolon free flap |
| • Clinical studies reporting surgical outcomes |
| • Studies written in English |
|
|
| • Review articles |
| • Studies including pedicled ileocolon flaps |
| • Studies including pedicled ileocolon flaps with microvascular blood flow augmentation |
| • Preclinical studies or animal studies |
Fig. 1Standard isoperistaltic ileocolon free flap (indication: total pharyngolaryngectomy).
Fig. 2Detubularized ileocolon free flap (indication: anterior pharyngolaryngectomy).
Fig. 3Ileocolon patch flap (indication: laryngectomy).
Fig. 4Antiperistaltic inset of an ileocolon funnel flap with ileocecal valvuloplasty (indication: high pharyngeal and low esophageal defects).
Fig. 5Chimaeric seromuscular flap (indication: prevent anastomotic leakage).
Fig. 6Systematic search flow diagram.
Overview, general characteristics of patients, and quality assessment of included studies
| Author, year | OCEBM | NOS | Observation period (years) |
Patients (
| M | F | Age (y) |
Flaps (
| Indication | Follow-up (mo) |
|---|---|---|---|---|---|---|---|---|---|---|
|
Kawahara et al (1992)
| 4 |
5
| 1987–1992 | 6 | 4 | 2 | 63.5 (range: 50–78) | 6 | Neoplastic disease | 11.66 (range: 6–23) |
|
Sartoris et al (1999)
| 4 |
5
| 1998–1999 | 6 | 3 | 3 | Range: 45–65 | 6 | Squamous cell carcinoma | Range: 8–12 |
|
Succo et al (2000)
| 4 |
5
| 1998–2000 | 8 | 5 | 3 | 58.25 (range: 45–68) | 8 | Squamous cell carcinoma | 13.5 (range: 9–24) |
|
Kobayashi et al (2003)
| 4 |
5
| 1998–2000 | 7 | 5 | 2 | 58.85 (range: 20–71) | 7 | Thyroid carcinoma | 29.8 (range: 23–48) |
|
Mardini et al (2004)
| 4 |
5
| 2001–2002 | 9 | 9 | 0 | 58 (range: 46–73) | 9 | Hypopharyngeal cancer | 7 |
|
Leu et al (2005)
| 4 |
5
| 2002–2003 | 12 | 12 | 0 | 48.2 (range: 33–61) | 12 |
Hypopharyngeal squamous cell carcinoma (
| 16.5 (range:12–20) |
|
Chen et al (2006)
| 4 | 5 | 2002–204 | 12 | 11 | 1 | 62.8 ± 11.4 | 6 |
Laryngeal cancer (
| 7 (range: 1.5–24) |
|
Rampazzo et al (2008)
| 4 | 5 | 2003–2007 | 34 | 32 | 2 | NR | 34 |
Hypopharyngeal cancer (
| 19 (range: 4–56) |
|
Leu et al (2008)
| 4 |
4
| 2002–2004 | 15 | 15 | 0 | 49.8 (range: 33–61) | 15 |
Hypopharyngeal squamous cell carcinoma (
| 24 |
|
Hsiao et al (2009)
| 4 |
5
| 2001–2005 | 16 | 16 | 0 | 51.9 (range: 33–69) | 16 | Squamous cell carcinoma: | 15.6 (range: 4–36) |
|
Tai et al (2009)
| 4 | 4 | 2003–2006 | 13 | 13 | 0 | 54.3 (range: 44–63) | 13 |
Hypopharyngeal squamous cell carcinoma (
| 33 |
|
Karri et al (2011)
| 4 | 7 | 2004–2009 | 17 | 15 | 2 | 49 (range: 35–69) | 17 |
Hypopharyngeal cancer (
| 22 (range: 6–72) |
|
Rampazzo et al (2011)
| 4 | 5 | 2004–2008 | 35 | 33 | 2 | 57 (range: 38–80) | 35 |
Hypopharyngeal cancer (
| 34.2 |
|
Perrone et al (2012)
| 4 | 7 | 2004–2009 | 29 | 26 | 3 | 55.5 (range: 41–79) | 29 |
Hypopharyngeal cancer (
| 51 |
|
Gharb et al (2013)
| 4 | 6 | 1995–2009 | 14 | 13 | 1 | 59.14 (range: 45–73) | 14 |
Hypopharyngeal cancer (
| 28.07 (range: 12–40) |
|
Tsou et al (2016)
| 4 | 6 | 2011–2012 | 30 | NR | NR | NR | 30 |
Hypopharyngeal cancer (
| >3 |
| Chen et al (2018) 6 | 4 | 5 | 1988–2017 | 205 | NR | NR | NR | 191 |
Pharynx or larynx cancer (
| NR |
|
Yang et al (2019)
| 4 |
5
| 2013–2015 | 14 | 14 | 0 | 51 (range: 39–72) | 14 |
Cervical esophagus defects following oncological resection + failed free ALT flap reconstruction (
| 13.8 (range: 6–27) |
|
Lo Torto et al (2020)
| 4 | 6 | 2010–2015 | 37 | 35 | 2 | 54.1 (range: 38–78) | 37 |
Hypopharyngeal (
| 20 (range: 12–48) |
|
Manrique et al (2020)
| 4 | 6 | 2010–2015 | 34 | 29 | 5 | 54.4 (range: 44–60) | 34 |
Squamous cell carcinoma (
| NR |
|
Yegin et al (2020)
| 4 |
5
| 1983–2017 | 12 | 5 | 7 | 52 (range: 28–78) | 12 |
Pharyngolaryngeal stricture (
| 28.1 (range: 19–48) |
Abbreviations: BMI, body mass index; F, female; NOS, Newcastle–Ottawa Scale; M, male; NR, not reported; OCEBM, Oxford Centre for Evidence-Based Medicine: Levels of Evidence.
Risk of bias evaluated with the methodological quality assessment tool (MQAT) proposed by Murad et al. 11 for case reports and case series.
Oncologic treatment reported in included studies
| Study (year) |
Flaps (
| Cancer surgery |
Stage
| Prior chemo/radio therapy | Adjuvant RT | Adjuvant ChT |
|---|---|---|---|---|---|---|
|
Kawahara et al (1992)
| 6 |
PLE + B/L ND (
| NR |
Chemotherapy (
|
(
|
(
|
|
Sartoris et al (1999)
| 6 |
PLE + B/L ND ± HemiTh/subtotal Th (
| Advanced stage | NR |
(
| NR |
|
Succo et al (2000)
| 8 |
PLE + B/L ND (
| IV |
Chemotherapy (
|
(
|
(
|
|
Kobayashi et al (2003)
| 7 |
L + B/L ND + Th (
| NR |
Chemotherapy (
| NR | NR |
|
Mardini et al (2004)
| 9 | PLE | NR | NR | NR | NR |
|
Leu et al (2005)
| 12 |
PL (
|
III (
| NR |
(
|
(
|
|
Chen et al (2006)
| 6 |
L (
| NR | NR | NR | NR |
|
Rampazzo et al (2008)
| 34 |
L (
| NR | NR | NR |
(
|
|
Leu et al (2008)
| 15 |
PLE (
|
III (
| NR |
(
|
(
|
|
Hsiao et al (2009)
| 16 |
PL (
|
II (
| NR |
(
|
(
|
|
Tai et al (2009)
| 13 | NR |
III (
| NR |
(
|
(
|
|
Karri et al (2011)
| 17 |
Radiation (
| III and IV |
(
|
(
|
(
|
|
Rampazzo et al (2011)
| 35 | L | NR | NR |
(
|
(
|
|
Perrone et al (2012)
| 29 | NR | NR | NR |
(
| NR |
|
Gharb et al (2013)
| 14 | PL | NR | NR |
(
| NR |
|
Tsou et al (2016)
| 30 |
PL (
| NR |
(
|
(
| NR |
|
Chen et al (2018)
| 191 | PL | NR | NR | NR | NR |
|
Yang et al (2019)
| 14 |
PL (
| NR | NR | NR | NR |
|
Lo Torto et al (2020)
| 37 |
PL (
| NR | NR |
(
|
(
|
|
Manrique et al (2020)
| 34 | PL |
III (
|
(
| NR | NR |
|
Yegin et al (2020)
| 12 | NR | NR | NR |
(
| NR |
Abbreviations: B/L, bilateral; ChT, chemotherapy; G, glossectomy; HemiTh/HemTh, hemithyroidectomy; L, laryngectomy; ND, neck dissection; NR, not reported; PL, pharyngolaryngectomy; PLE, pharyngolaryngoesophagectomy; RT, radiotherapy; TELND, tracheoesophageal lymph node dissection; Th, thyroidectomy; U/L, unilateral.
Cancer staging using the tumor, node, metastasis (TNM) system for classification.
Overview of the type of flaps, surgical technique, and flap success rate of included studies
| Study (year) |
Flaps (
| Primary or secondary reconstruction | Type of flap | Supplementary surgical considerations | Recipient vessels | Surgical time (h) | Mean hospital stay (d) | Flap success (%) |
|---|---|---|---|---|---|---|---|---|
|
Kawahara et al (1992)
| 6 |
Primary (
| Standard ISO |
Cecal plication using the anterior and posterior wall of the cecum.Ileum is anastomosed to the trachea (E-E, 4–0 Vicryl) (
| IJV (E-S, 9–0) | NR | NR | 100 |
|
Sartoris et al (1999)
| 6 |
Primary (
|
Standard ISO (
| Lembert's stitches along the ileal tract | ECA or branch of ECA (9–0) | 10–12 | NR | 100 |
|
Succo et al (2000)
| 8 |
Primary (
|
Standard ISO (
| Ileotracheal anastomosis (E-E) | ECA | 9–12 | NR | 100 |
| Kobayashi et al (2003) | 7 |
Primary (
|
Patch (
| Patch to the hypopharyngeal defect (same size) | IJV (E-S) | NR | NR | 100 |
|
Mardini et al (2004)
| 9 | NR | Standard | Biologic dressing (Biobrane, Dow Hickam Pharmaceuticals, Inc., Sugar Land, Texas) | IJV (E-E) | NR | NR | 100 |
|
Leu et al (2005)
| 12 |
Primary (
| Standard | Ileotracheal anastomosis (E-E) | NR | NR | NR | 100 |
|
Chen et al (2006)
| 6 |
Secondary (
| Standard or Patch | NR | NR | NR | NR | 100 |
|
Rampazzo et al (2008)
| 34 |
Primary (
|
Standard ISO/ANTI (
| NR | NR | NR | 42 ± 20 | 100 |
|
Leu et al (2008)
| 15 |
Primary (
| Standard | Ileotracheal anastomosis (E-E) | NR | NR | NR | 100 |
|
Hsiao et al (2009)
| 16 |
Primary (
| Standard ISO | Ileotracheal anastomosis (E-E) | STA | NR | NR | 100 |
|
Tai et al (2009)
| 13 | NR | NR | NR | NR | NR | NR | 100 |
|
Karri et al (2011)
| 17 |
Primary (
|
Standard ISO (
|
Ileotracheal anastomosis (E-E) (
|
TCA (
| NR | 23.8(Range 21–37) | 100 |
|
Rampazzo et al (2011)
| 35 |
Primary (
|
Standard ISO (
| Ileotracheal anastomosis (E-E) | NR | NR | NR | 100 |
|
Perrone et al (2012)
| 29 |
Primary (
|
Ch-SM (
| A seromuscular flap (A 3-cm segment of the ileal loop) was sutured to the antero-lateral walls of the colooesophageal anastomosis. | NR | NR | NR | 100% |
|
Gharb et al (2013)
| 14 |
Primary (
|
Standard ISO (
| NR | NR | NR | NR | 100 |
|
Tsou et al (2016)
| 30 | NR |
Standard ISO (
|
Ileum segment: <7 cm (
| TCA | NR | NR | 100 |
|
Chen et al (2018)
| 191 | NR | Standard ISO | NR | NR | NR | NR | 97 |
|
Yang et al (2019)
| 14 |
Secondary (
| Standard | NR | TCA | NR | NR | 92.85 |
|
Lo Torto et al (2020)
| 37 |
Primary (
| Standard ANTI | NR | NR | NR | 24.8 ± 12 | 100 |
|
Manrique et al (2020)
| 34 | NR | Standard | NR | NR | 11.5 (range: 8–14.5) | NR | 97 |
|
Yegin et al (2020)
| 12 |
Revision (
| NR |
Revision of the Free Ileocolon flap with pedicle transection (
| NR | NR | NR | 100 |
Abbreviations: ANTI, anti-peristaltic ileocolon free flap; APA, ascending pharyngeal artery; Ch-SM, chimeric seromuscular flap; DeTUBE, detubularized ileocolon free flap; ECA, external carotid artery; E-E, end to end; EJV, external jugular vein; E-S, end to side; IJV, internal jugular vein; ISO, iso-peristaltic ileocolon free flap; NR, not reported; rTCA, retrograde transverse cervical artery; TAA, thoracoacromial artery; TAV, thoracoacromial vein; SCA, superficial cervical artery; SMA, superior mesenteric artery; STA, superior thyroid artery; STV, superior thyroid vein.
Recipient and donor site complications, and additional surgical procedures reported in included studies
| Study (year) |
Flaps (
| Complications recipient site | Complications donor site | Additional surgeries |
|---|---|---|---|---|
|
Kawahara et al (1992)
| 6 |
Death (hepatic failure, preexisting cirrhosis;
| No abdominal complications |
Revision of venous congestion (
|
|
Sartoris et al (1999)
| 6 |
Erosive gastric hemorrhage (
|
Eventration POD 17 (
| None |
|
Succo et al (2000)
| 8 |
Erosive gastric hemorrhage (
|
Eventration POD 17 (
| NR |
|
Kobayashi et al (2003)
| 7 |
Death (rupture of carotid artery) (
| NR | NR |
|
Mardini et al (2004)
| 9 |
Pharyngocutaneous fistula (
|
Superficial abdominal wound infection (
|
Pectoralis major muscle flap for fistula (
|
|
Leu et al (2005)
| 12 |
Suicide (
| No abdominal complications | NR |
|
Chen et al (2006)
| 6 | NR | NR | NR |
|
Rampazzo et al (2008)
| 34 |
Hypocalcemia (
|
Pseudomembranous colitis (
| None |
|
Leu et al (2008)
| 15 | NR | NR | NR |
|
Hsiao et al (2009)
| 16 |
Late flap necrosis (pedicle damaged in another operation) (
| No abdominal complications |
Pharyngocutaneous fistula closure (
|
|
Tai et al (2009)
| 13 | NR | NR | NR |
|
Karri et al (2011)
| 17 |
Partial flap necrosis (
| Self-limited diarrhea (a few) |
Release of stricture (
|
|
Rampazzo et al (2011)
| 35 |
Incompetence of the ileocecal valve (
| NR |
Closure of the pathologic tracheoesophageal fistula (
|
|
Perrone et al (2012)
| 29 |
Anastomotic leakage (
| NR | DP flap or PMMC flap for fistula |
|
Gharb et al (2013)
| 14 |
Incontinence of the ileocecal valve (
| NR |
Correct incontinence of ileocecal valve (
|
|
Tsou et al (2016)
| 30 |
Vascular compromise (
| NR |
Vascular compromise (
|
|
Chen et al (2018)
| 191 |
Death pneumonia POD 13 (
|
Intestinal adhesion (
|
Local skin flaps (
|
|
Yang et al (2019)
| 14 |
Flap failure (
|
Ventral hernia (
|
PM flap: flap failure (
|
|
Lo Torto et al (2020)
| 37 |
Surgical revision due to arterial thrombosis (
|
Ileus (
|
Microsurgical revision (
|
|
Manrique et al (2020)
| 34 |
Hypotension >requiring vasopressors (
| NR |
Partial flap loss revision (
|
|
Yegin et al (2020)
| 12 |
Immediate paleness and loss of peristalsis in the two cases of arterial pedicle division (
| NR/NA |
Anterior wall reconstruction (
|
Abbreviations: DP, deltopectoral flap; NA, not applicable; NR, not reported; PM, pectoralis major flap; PMMC, pectoralis major myocutaneous flap; POD, postoperative day; SSTG, split-thickness skin graft.
Overview of functional outcomes following reconstruction of the aerodigestive tract with an ileocolon free flap
| Study (year) |
Flaps (
| QoL | Swallowing | Speech |
|---|---|---|---|---|
|
Kawahara et al (1992)
| 6 | NR |
Swallow without aspiration (
| Fundamental frequency: 83 ± 23.2 to 138 ± 55.8 Hz |
|
Sartoris et al (1999)
| 6 | NR |
Swallowing without aspiration (
| Voice characteristics were not altered after radiotherapy |
|
Succo et al (2000)
| 8 | NR |
Deterioration of swallowing after RT (
|
Fairly good level of intelligibility (
|
|
Kobayashi et al (2003)
| 7 | NR | Swallow without aspiration | Speak naturally by practicing themselves |
|
Mardini et al (2004)
| 9 | NR |
Solid and semisolid diet (
| NR |
|
Leu et al (2005)
| 12 | NR |
Swallow meals without aspiration (
| Evaluation 6 months after surgery: speech efficacy 55% (range 10–80%) |
|
Chen et al (2006)
| 6 | • HADS-anxiety: VTS, 5.50 ± 6.03; PAL, 8.83 ± 4.71 | Swallowing function: VTS, 5.83 ± 1.17; PAL, 5.17 ± 1.72 | Intelligibility: VTS, 4.67 ± 0.82; PAL, 2.00 ± 1.55. |
|
Rampazzo et al (2008)
| 34 | NR |
Satisfactory swallowing (
| NR |
|
Leu et al (2008)
| 15 | NR |
• 6 months postoperatively (
| NR |
|
Hsiao et al (2009)
| 16 | NR |
Feeding pattern 3 month after CCRT: liquid diet (
| Phonation efficacy 3 months after CCRT (%): 48% |
|
Tai et al (2009)
| 13 | NR | The 5 patients treated with IMRT appeared to have better restoration of phonation and swallowing ability as well as less severe acute dermatitis and mucositis than did the 8 who had treated with 2DRT | NR |
|
Karri et al (2011)
| 17 |
EORTC QLQ-C30 and H&N35 (
|
Soft-diet oral feeding by 4 weeks (
|
Speech (
|
|
Rampazzo et al (2011)
| 35 | NR |
Aspiration: (
| NR |
|
Perrone et al (2012)
| 29 | NR | 7-point Likert's scale (1, severe complaints and an inability to swallow; 7, swallowing without complaints): median swallowing score, 5; 50% had only minimal complaints and had dry swallowing at the last follow-up. | 5-point Likert's scale (1, no voice; 5, very good outcome): median speech score, 4; 50% spoke long sentences with an intelligible voice and moderate loudness. |
|
Tsou et al (2016)
| 30 | NR | 7-point Likert's scale (1, severe complaints and an inability to swallow; 7, swallowing without any complaints): | 5-point Likert's scale (1, no voice; 5, very good outcome) |
|
Chen et al (2018)
| 191 |
EORTC QLQ-C30 (
|
7-point Likert's scale (1, severe complaints and an inability to swallow; 7, swallowing without complaints;
| 5-point Likert's scale (1, no voice; 5, very good outcome): good result (score >12), 64%; moderate result (score 9–11), 21%; unsatisfactory (<9), 6%. |
|
Yang et al (2019)
| 14 | NR | Time before restoration of swallowing: 1.35 months | |
|
Lo Torto et al (2020)
| 37 | NR |
7-point Likert's scale (1, severe complaints and an inability to swallow; 7, swallowing without complaints;
|
Voice analysis (
|
|
Yegin et al (2020)
| 12 | NR |
Oral intake and swallowing rehabilitation at 1 month postoperatively (
| NR |
Abbreviations: CCRT, concurrent chemoradiotherapy; EORT QLQ-C30, the EORTC core quality of life questionnaire F0, frequency; H&N35, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module; HADS, Hospital Anxiety and Depression Scale; IMRT, intensity-modulated radiation therapy; MPT, mean phonation time; NR, not reported; PAL, Pneumatic artificial larynx; QoL, quality of life; RT, radiotherapy; VTS, voice tube shunt; 2DRT, conventional radiotherapy.